Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

20133,301 citationsJournal Article

Authors

Chris Parker · San Antonio College

Sten Nilsson · San Antonio College

Daniel Heinrich · San Antonio College

Svein Inge Helle · San Antonio College

Joe M. O’Sullivan · San Antonio College

Sophie D. Fosså · San Antonio College

Aleš Chodacki ·

Abstract

In this study, which was terminated for efficacy at the prespecified interim analysis, radium-223 improved overall survival. (Funded by Algeta and Bayer HealthCare Pharmaceuticals; ALSYMPCA ClinicalTrials.gov number, NCT00699751.).

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Bone health and treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 369, Issue 3, pp. 213-223

DOI: 10.1056/nejmoa1213755

Field-Weighted Citation Impact: 199.31